Margarida Maia, PhD, science writer —

Margarida is a biochemist (University of Porto, Portugal) with a PhD in biomedical sciences (VIB and KULeuven, Belgium). Her main interest is science communication. She is also passionate about design and the dialogue between art and science.

Articles by Margarida Maia

COR588, New Gingipain Inhibitor, Safe to Take Once Daily

COR588, Quince Therapeutics’ investigational oral small molecule for mild to moderate Alzheimer’s disease, appears to be safe and well tolerated, according to results from a Phase 1 trial, the company announced. (The company was known as Cortexyme until Aug. 1.) The recently completed single and multiple ascending dose clinical…

Seelos Gears Up for Pilot Study in Australia Testing SLS-005

Seelos Therapeutics is gearing up for a pilot study, in Australia, testing SLS-005 (trehalose) — its investigational therapy for people with Alzheimer’s disease — after receiving an acknowledgment letter from the country’s regulatory body for clinical trials. The letter, from the Australian Government Department of Health Therapeutic Goods…

Rethink-ALZ.com, New Website on Simufilam Phase 3 Studies, Is Live

Cassava Sciences has launched a new website, called Rethink-ALZ.com, to make it easier for anyone interested to access information about two Phase 3 clinical studies of simufilam, the company’s oral investigational therapy for mild-to-moderate Alzheimer’s disease. The trials, dubbed RETHINK-ALZ and REFOCUS-ALZ, are ongoing in the U.S. and Canada,…

Aduhelm Developers Step Up Phase 4 Confirmatory Study

Biogen and Eisai are stepping up their Phase 4 post-marketing confirmatory study to verify that Aduhelm (aducanumab) is meeting the expected clinical benefit in patients with early-stage Alzheimer’s disease. The companies plan to submit the study’s final protocol for review to the U.S. Food and Drug Administration…